Doxycycline Plus Trimethoprim-sulfamethoxazole Versus Doxycycline Plus Rifampicin in Treatment of Brucellosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202210778524094

Enrollment

100

Registered

2022-10-13

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis

Interventions

Doxycycline plus Trimethoprim sulfamethoxazole

Doxycycline plus Rifampicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: consecutive 100 patients with brucellosis who attend our outpatient clinic and inpatient ward will be enrolled in our study.

Exclusion criteria

Exclusion criteria: Complicated localized brucellosis (spondylitis, endocarditis, meningoencephalitis). Age less than 18 years Pregnancy Receiving antibiotics for more than 1 week before enrolment

Design outcomes

Primary

Measure	Time frame
Successful Treatment ;Failure of therapy;Relapse	—

Secondary

Measure	Time frame
Stoppage of treatment	—

Countries

Egypt

Contacts

Public ContactMohammed Abdel Mawgood

Assistant Professor

Muhammad2013@azhar.edu.eg00201113528652

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026